Literature DB >> 27826559

Immune surveillance of liver cancer in non-alcoholic fatty liver disease: excess lipids cause CD4 T-cells loss and promote hepatocellular carcinoma development.

Ralf Weiskirchen1, Frank Tacke2.   

Abstract

Entities:  

Year:  2016        PMID： 27826559      PMCID： PMC5075830          DOI： 10.21037/hbsn.2016.09.10

Source DB:  PubMed          Journal:  Hepatobiliary Surg Nutr        ISSN： 2304-3881            Impact factor:   7.293


× No keyword cloud information.
  26 in total

Review 1.  Obesity and infection.

Authors:  Matthew E Falagas; Maria Kompoti
Journal:  Lancet Infect Dis       Date:  2006-07       Impact factor: 25.071

Review 2.  Nonalcoholic fatty liver disease and hepatocellular carcinoma.

Authors:  Heinz Zoller; Herbert Tilg
Journal:  Metabolism       Date:  2016-01-23       Impact factor: 8.694

3.  Adaptive immunity suppresses formation and progression of diethylnitrosamine-induced liver cancer.

Authors:  Carlo Schneider; Andreas Teufel; Tetyana Yevsa; Frank Staib; Anja Hohmeyer; Gudrun Walenda; Henning W Zimmermann; Mihael Vucur; Sebastian Huss; Nikolaus Gassler; Hermann E Wasmuth; Sergio A Lira; Lars Zender; Tom Luedde; Christian Trautwein; Frank Tacke
Journal:  Gut       Date:  2012-01-20       Impact factor: 23.059

4.  Obesity is independently associated with infection in hospitalised patients with end-stage liver disease.

Authors:  V Sundaram; A Kaung; A Rajaram; S C Lu; T T Tran; N N Nissen; A S Klein; R Jalan; M R Charlton; C Y Jeon
Journal:  Aliment Pharmacol Ther       Date:  2015-10-13       Impact factor: 8.171

5.  Progression from Nonalcoholic Fatty Liver to Nonalcoholic Steatohepatitis Is Marked by a Higher Frequency of Th17 Cells in the Liver and an Increased Th17/Resting Regulatory T Cell Ratio in Peripheral Blood and in the Liver.

Authors:  Monika Rau; Anne-Kristin Schilling; Jan Meertens; Ilona Hering; Johannes Weiss; Christian Jurowich; Theodor Kudlich; Heike M Hermanns; Heike Bantel; Niklas Beyersdorf; Andreas Geier
Journal:  J Immunol       Date:  2015-11-30       Impact factor: 5.422

6.  Ranking the toxicity of fatty acids on Jurkat and Raji cells by flow cytometric analysis.

Authors:  T M Lima; C C Kanunfre; C Pompéia; R Verlengia; R Curi
Journal:  Toxicol In Vitro       Date:  2002-12       Impact factor: 3.500

7.  Reversible tumorigenesis by MYC in hematopoietic lineages.

Authors:  D W Felsher; J M Bishop
Journal:  Mol Cell       Date:  1999-08       Impact factor: 17.970

Review 8.  Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19·2 million participants.

Authors: 
Journal:  Lancet       Date:  2016-04-02       Impact factor: 79.321

Review 9.  Role of lymphocytes in liver cancer.

Authors:  Jana C Mossanen; Frank Tacke
Journal:  Oncoimmunology       Date:  2013-10-21       Impact factor: 8.110

10.  NAFLD causes selective CD4(+) T lymphocyte loss and promotes hepatocarcinogenesis.

Authors:  Chi Ma; Aparna H Kesarwala; Tobias Eggert; José Medina-Echeverz; David E Kleiner; Ping Jin; David F Stroncek; Masaki Terabe; Veena Kapoor; Mei ElGindi; Miaojun Han; Angela M Thornton; Haibo Zhang; Michèle Egger; Ji Luo; Dean W Felsher; Daniel W McVicar; Achim Weber; Mathias Heikenwalder; Tim F Greten
Journal:  Nature       Date:  2016-03-02       Impact factor: 49.962
View more
  3 in total

1.  Clinicopathologic and prognostic significance of regulatory T cells in patients with hepatocellular carcinoma: a meta-analysis.

Authors:  Lejia Sun; Gang Xu; Wenjun Liao; Huayu Yang; Haifeng Xu; Shunda Du; Haitao Zhao; Xin Lu; Xinting Sang; Yilei Mao
Journal:  Oncotarget       Date:  2017-06-13

2.  Anti-cancer efficacy of biotinylated chitosan nanoparticles in liver cancer.

Authors:  Mingrong Cheng; Weiping Zhu; Qing Li; Dejian Dai; Yiming Hou
Journal:  Oncotarget       Date:  2017-07-10

3.  Impact of regulatory T cells on the prognosis of hepatocellular carcinoma: A protocol for systematic review and meta analysis.

Authors:  Xinhui Shi; Qisong Li; Yungang Wang
Journal:  Medicine (Baltimore)       Date:  2021-01-22       Impact factor: 1.889
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.